BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 28556564)

  • 1. Associations between ABO blood groups and pancreatic ductal adenocarcinoma: influence on resection status and survival.
    El Jellas K; Hoem D; Hagen KG; Kalvenes MB; Aziz S; Steine SJ; Immervoll H; Johansson S; Molven A
    Cancer Med; 2017 Jul; 6(7):1531-1540. PubMed ID: 28556564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ABO blood type, smoking status, other risk factors and prognosis of pancreatic ductal adenocarcinoma.
    Li SS; Zhou CY; Liao R; Xiong L; Weng NN; Zhao YQ; Mason C; Gou HF; Yi C; Zhu Q
    Medicine (Baltimore); 2020 Apr; 99(14):e19413. PubMed ID: 32243360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variant ABO blood group alleles, secretor status, and risk of pancreatic cancer: results from the pancreatic cancer cohort consortium.
    Wolpin BM; Kraft P; Xu M; Steplowski E; Olsson ML; Arslan AA; Bueno-de-Mesquita HB; Gross M; Helzlsouer K; Jacobs EJ; LaCroix A; Petersen G; Stolzenberg-Solomon RZ; Zheng W; Albanes D; Allen NE; Amundadottir L; Austin MA; Boutron-Ruault MC; Buring JE; Canzian F; Chanock SJ; Gaziano JM; Giovannucci EL; Hallmans G; Hankinson SE; Hoover RN; Hunter DJ; Hutchinson A; Jacobs KB; Kooperberg C; Mendelsohn JB; Michaud DS; Overvad K; Patel AV; Sanchéz MJ; Sansbury L; Shu XO; Slimani N; Tobias GS; Trichopoulos D; Vineis P; Visvanathan K; Virtamo J; Wactawski-Wende J; Watters J; Yu K; Zeleniuch-Jacquotte A; Hartge P; Fuchs CS
    Cancer Epidemiol Biomarkers Prev; 2010 Dec; 19(12):3140-9. PubMed ID: 20971884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between ABO Blood Group Alleles and Pancreatic Cancer Is Modulated by Secretor (FUT2) Genotype, but Not Lewis Antigen (FUT3) Genotype.
    Kim J; Yuan C; Amundadottir LT; Wolpin BM; ; Klein AP; ; Risch HA; Kraft P
    Cancer Epidemiol Biomarkers Prev; 2023 Sep; 32(9):1242-1248. PubMed ID: 37342060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
    Distler M; Pilarsky E; Kersting S; Grützmann R
    Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ABO blood groups and pancreatic cancer risk and survival: results from the PANcreatic Disease ReseArch (PANDoRA) consortium.
    Rizzato C; Campa D; Pezzilli R; Soucek P; Greenhalf W; Capurso G; Talar-Wojnarowska R; Heller A; Jamroziak K; Khaw KT; Key TJ; Bambi F; Landi S; Mohelnikova-Duchonova B; Vodickova L; Büchler MW; Bugert P; Vodicka P; Neoptolemos JP; Werner J; Hoheisel JD; Bauer AS; Giese N; Canzian F
    Oncol Rep; 2013 Apr; 29(4):1637-44. PubMed ID: 23403949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Re-evaluation of ABO gene polymorphisms detected in a genome-wide association study and risk of pancreatic ductal adenocarcinoma in a Chinese population.
    Xu HL; Cheng JR; Zhang W; Wang J; Yu H; Ni QX; Risch HA; Gao YT
    Chin J Cancer; 2014 Feb; 33(2):68-73. PubMed ID: 23816557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical characteristics of second primary pancreatic cancer.
    Jo JH; Cho IR; Jung JH; Lee HS; Chung MJ; Bang S; Park SW; Chung JB; Song SY; Park JY
    PLoS One; 2017; 12(6):e0179784. PubMed ID: 28650984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios.
    Asari S; Matsumoto I; Toyama H; Shinzeki M; Goto T; Ishida J; Ajiki T; Fukumoto T; Ku Y
    Surg Today; 2016 May; 46(5):583-92. PubMed ID: 26108488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ABO histo-blood group might modulate predisposition to Crohn's disease and affect disease behavior.
    Forni D; Cleynen I; Ferrante M; Cassinotti A; Cagliani R; Ardizzone S; Vermeire S; Fichera M; Lombardini M; Maconi G; de Franchis R; Asselta R; Biasin M; Clerici M; Sironi M
    J Crohns Colitis; 2014 Jun; 8(6):489-94. PubMed ID: 24268527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ABO blood group alleles and the risk of pancreatic cancer in a Japanese population.
    Nakao M; Matsuo K; Hosono S; Ogata S; Ito H; Watanabe M; Mizuno N; Iida S; Sato S; Yatabe Y; Yamao K; Ueda R; Tajima K; Tanaka H
    Cancer Sci; 2011 May; 102(5):1076-80. PubMed ID: 21306478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fucosyltransferase 2 (FUT2) non-secretor status and blood group B are associated with elevated serum lipase activity in asymptomatic subjects, and an increased risk for chronic pancreatitis: a genetic association study.
    Weiss FU; Schurmann C; Guenther A; Ernst F; Teumer A; Mayerle J; Simon P; Völzke H; Radke D; Greinacher A; Kuehn JP; Zenker M; Völker U; Homuth G; Lerch MM
    Gut; 2015 Apr; 64(4):646-56. PubMed ID: 25028398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and Validation of a Biomarker Signature in Patients With Resectable Pancreatic Cancer via Genome-Wide Screening for Functional Genetic Variants.
    Dimitrakopoulos C; Vrugt B; Flury R; Schraml P; Knippschild U; Wild P; Hoerstrup S; Henne-Bruns D; Wuerl P; Graf R; Breitenstein S; Bond G; Beerenwinkel N; Grochola LF
    JAMA Surg; 2019 Jun; 154(6):e190484. PubMed ID: 30942874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pancreatic cancer risk and ABO blood group alleles: results from the pancreatic cancer cohort consortium.
    Wolpin BM; Kraft P; Gross M; Helzlsouer K; Bueno-de-Mesquita HB; Steplowski E; Stolzenberg-Solomon RZ; Arslan AA; Jacobs EJ; Lacroix A; Petersen G; Zheng W; Albanes D; Allen NE; Amundadottir L; Anderson G; Boutron-Ruault MC; Buring JE; Canzian F; Chanock SJ; Clipp S; Gaziano JM; Giovannucci EL; Hallmans G; Hankinson SE; Hoover RN; Hunter DJ; Hutchinson A; Jacobs K; Kooperberg C; Lynch SM; Mendelsohn JB; Michaud DS; Overvad K; Patel AV; Rajkovic A; Sanchéz MJ; Shu XO; Slimani N; Thomas G; Tobias GS; Trichopoulos D; Vineis P; Virtamo J; Wactawski-Wende J; Yu K; Zeleniuch-Jacquotte A; Hartge P; Fuchs CS
    Cancer Res; 2010 Feb; 70(3):1015-23. PubMed ID: 20103627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of ABO blood group with survival following pancreatoduodenectomy for pancreatic ductal adenocarcinoma.
    Williams H; Jajja MR; Hashmi SS; Maxwell D; Cardona K; Maithel SK; Russell MC; Sarmiento JM; Winer JH; Kooby DA
    HPB (Oxford); 2020 Nov; 22(11):1557-1562. PubMed ID: 32146119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of replication of seven pancreatic cancer susceptibility loci identified in two Asian populations.
    Campa D; Rizzato C; Bauer AS; Werner J; Capurso G; Costello E; Talar-Wojnarowska R; Jamroziak K; Pezzilli R; Gazouli M; Khaw KT; Key TJ; Bambi F; Mohelnikova-Duchonova B; Heller A; Landi S; Vodickova L; Theodoropoulos G; Bugert P; Vodicka P; Hoheisel JD; Delle Fave G; Neoptolemos JP; Soucek P; Büchler MW; Giese N; Canzian F
    Cancer Epidemiol Biomarkers Prev; 2013 Feb; 22(2):320-3. PubMed ID: 23250936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of FUT2 and ABO with Crohn's disease in Koreans.
    Ye BD; Kim BM; Jung S; Lee HS; Hong M; Kim K; Moon JW; Baek J; Oh EH; Hwang SW; Park SH; Yang SK; Song K
    J Gastroenterol Hepatol; 2020 Jan; 35(1):104-109. PubMed ID: 31260595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival.
    Shin SH; Kim SC; Hong SM; Kim YH; Song KB; Park KM; Lee YJ
    Pancreas; 2013 Mar; 42(2):216-22. PubMed ID: 23344532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AB0 blood group and prognosis in patients with pancreatic cancer.
    Rahbari NN; Bork U; Hinz U; Leo A; Kirchberg J; Koch M; Büchler MW; Weitz J
    BMC Cancer; 2012 Jul; 12():319. PubMed ID: 22838843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is chronic hepatitis B infection a protective factor for the progression of advanced pancreatic ductal adenocarcinoma? An analysis from a large multicenter cohort study.
    Chen Q; Ning Z; Wang L; Ying H; Dong S; Zhang C; Shen X; Guo Y; Chen H; Zhu X; Shen Y; Shi W; Hua Y; Wang K; Lin J; Xu L; Chen L; Feng L; Zhang X; Xie J; Sun B; Sun Y; Gu W; Kang M; Tang Z; Chen Z; Chen Z; Liu L; Yu J; Li Z; Meng Z
    Oncotarget; 2016 Dec; 7(51):85603-85612. PubMed ID: 27811354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.